A Phase 4 interventional study of ACE Reno in Hypertensive Nephropathy, Auto Immune Disorders and Chronic Kidney Disease, sponsored by Ace Cells Lab Limited. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Ace Cells Lab Limited · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 4th largest by planned enrollment of the 44 interventional ones that give a count, is one of 17 that started in 2025, is one of 8 in phase 4, reaches primary completion later than 17 of the 27 other live ones, and was the 47th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Future University in Egypt · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18+
Mansoura University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 8 · Phase 4 8
First in 2013; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 64 across the 44 interventional studies, 110 across the 20 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 64 have an industry lead sponsor. The 10 most frequent:
Ace Cells Lab Limited is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Ace Cells Lab Limited has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies in Renal Insufficiency, Chronic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07706582Beni-Suef UniversityManagement of Iron Deficiency Anemia in Hemodialysis Patients | 2026-12 |
| NCT03436368Nazmy Edward SeifContinuous Spinal Anesthesia in Renal Transplantation | 2026-12 |
| NCT03778944Nazmy Edward SeifEnhancing Renal Graft Function During Donor Anesthesia | 2026-12 |
| NCT07640919Sohag UniversityPatterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria/proteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux/UTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-transplant proteinuria.
Nephropathy remains a global health burden, with \~9-10% of the population affected by chronic kidney disease (CKD), equating to >750 million individuals worldwide. The socioeconomic costs are substantial: in England CKD costs \~£7 billion annually, projected to rise to \~£14 billion by 2033; in Malaysia, prevalence rose from 9% to 15.5% within 7 years; in Egypt, CKD imposes heavy familial and financial burdens, especially for pediatric patients; in Turkey, CKD is among the top causes of disability, linked to the rising tide of diabetes, obesity, and hypertension.
ACE Reno is designed to address multiple drivers of CKD progression - glomerulosclerosis, fibrosis, endothelial dysfunction, and maladaptive RAAS/aldosterone signaling - through its peptide components that mimic antifibrotic (BMP-7, HGF, Klotho-like) and vasodilatory/cGMP-mediated (natriuretic peptide-like) pathways.
Study Objectives
Primary Objective:
To evaluate the effect of ACE Reno on urinary albumin-to-creatinine ratio (ACR) after 12 weeks of treatment in patients with nephropathy of diverse etiologies.
Secondary Objectives:
To assess the effect of ACE Reno on estimated glomerular filtration rate (eGFR) slope.
To evaluate changes in proteinuria, blood pressure, and patient-reported outcomes.
To assess safety and tolerability.
Exploratory Objectives:
To explore biomarker changes (e.g., TGF-β, cGMP, NGAL, KIM-1). To assess durability of response up to 6 months in responders. Investigational Product (IP) ACE Reno is a sublingual solution (1 mL four times daily for 12 weeks) containing a standardized panel of low-molecular-weight bioactive peptides and amino acids.
Key peptide domains include:
BMP-7-like sequences countering TGF-β-driven fibrosis. HGF-like fragments supporting epithelial repair. Klotho-like motifs antagonizing profibrotic pathways and RAAS/Wnt activity. Natriuretic-peptide-like domains enhancing cGMP signaling, with anti-fibrotic, vasodilatory, and endothelial-protective effects.
No genetic material is present; formulation is peptide-based only. Study Design Type: Prospective, multicenter, interventional, open-label. Model: Single-arm with within-patient comparisons. Duration: 12 weeks treatment + 4 weeks post-treatment safety follow-up. Visits: Screening, Baseline (Day 0), Week 4, Week 8, Week 12, and Week 16 safety call.
Participants
Inclusion:
Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi/ARB, SGLT2i, or MRA allowed.
Exclusion:
Dialysis at baseline. Recent kidney transplant (\<12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components. Categories (Strata: 17 Subgroups) Diabetic nephropathy - microalbuminuria Diabetic nephropathy - macroalbuminuria Diabetic nephropathy - CKD Stage 3 Diabetic nephropathy - CKD Stage 4-5 (non-dialysis) Hypertensive nephropathy - microalbuminuria Hypertensive nephropathy - proteinuric CKD Hypertensive nephropathy - advanced CKD (3-5) Autoimmune nephropathy - Class II-III Autoimmune nephropathy - Class IV-V Reflux nephropathy - mild/moderate scarring Reflux nephropathy - severe scarring Chronic glomerulonephritis - nephrotic range proteinuria Chronic glomerulonephritis - CKD \<60 mL/min/1.73m² CKD of unknown etiology - Stage 1-2 CKD of unknown etiology - Stage 3-4 ESRD pre-dialysis (eGFR \<15) Post-transplant CKD with proteinuria Sample Size and Rationale
Primary endpoint powering (paired design):
Detect 30% reduction in ACR (δ = ln(0.70) = -0.357), assuming σ = 0.8, r = 0.6 → \~32 analyzable patients needed.
Planned enrollment (pooled cohort, with 17 categories):
\~182 analyzable patients (\~214 enrolled allowing for 15% attrition). Each category will include a minimum of 8-12 patients (more for common etiologies such as diabetic proteinuria).
Total enrollment stratified by prevalence across categories. Endpoints
Primary Endpoint:
Change in urinary ACR from baseline to Week 12 (log-transformed).
Secondary Endpoints:
Change in eGFR slope. Change in 24-h proteinuria (selected patients). Blood pressure change. Patient-reported outcomes (KDQOL-36, EQ-5D). Safety (hyperkalemia, creatinine rise, liver tests, hematology).
Exploratory Endpoints:
Biomarker profiles (TGF-β, cGMP, NGAL, KIM-1). Hospitalization rate. Extended follow-up outcomes at 6 months. Follow-Up Plan
Monthly Visits (Week 4, 8, 12):
Clinical: BP, vitals, weight, adherence. Labs: creatinine/eGFR, electrolytes, liver panel, CBC, urine ACR. Safety: hyperkalemia, creatinine rise. PROs brief (fatigue, QoL).
Final (Week 12):
Primary endpoint assessment (duplicate ACR). PROs full set. Investigator global assessment.
Safety Call (Week 16):
AE/SAE resolution, concomitant therapy updates. Statistical Analysis Primary analysis: Paired t-test and mixed model for repeated measures (MMRM) on log(ACR).
Secondary: eGFR slope via linear mixed model, BP change via ANCOVA, responder rate (≥30% reduction in ACR).
Subgroups: Category-by-time interaction analysis; forest plots for effect estimates.
Multiplicity: Subgroup effects exploratory; overall primary endpoint tested at α=0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ACE Reno, a standardized oral transmucosal solution containing low-molecular-weight bioactive peptides and amino acids. The formulation is designed to engage antifibrotic (BMP-7-like, HGF-like, Klotho-like) and vasodilatory/natriuretic peptide-like pathways relevant to glomerular and tubulointerstitial function. No genetic material is present; formulation is peptide-based only.
Drug: ACE Reno
1 ml sublingual 4 times daily for 12 weeks
Change in Urinary Albumin-to-Creatinine Ratio (ACR)
Percent change in log-transformed urinary ACR measured from first-morning urine samples. The primary analysis compares baseline to Week 12 values
Time frame: 12 weeks
Change in Estimated Glomerular Filtration Rate (eGFR) slope
eGFR calculated from serum creatinine using CKD-EPI; slope analyzed via linear mixed model.
Time frame: Baseline, Week 4, Week 8, Week 12
Change in 24-hour Proteinuria
Absolute and percent change in 24-hour urinary protein excretion.
Time frame: Baseline to Week 12 (subset of participants with baseline nephrotic-range proteinuria)
Change in Blood Pressure
tp adjust BP : systolic \<=140 Diastolic \>100 up to 60 mmHg
Time frame: Baseline, Week 4, Week 8, Week 12
Safety and Tolerability
measure 'Full blood count before and after 16 weeks
Time frame: Throughout treatment and up to Week 16 follow-up
Safety and Tolerability
measure ALT before and after 16 weeks
Time frame: Throughout treatment and up to Week 16 follow-up
Safety and Tolerability
measure 'AST before and after 16 weeks
Time frame: Throughout treatment and up to Week 16 follow-up
Safety and Tolerability
measure Bilirubin before and after 16 weeks
Time frame: Throughout treatment and up to Week 16 follow-up
Safety and Tolerability
measure 'Urea before and after 16 weeks
Time frame: Throughout treatment and up to Week 16 follow-up
Safety and Tolerability
measure 'Creatinine before and after 16 weeks
Time frame: Throughout treatment and up to Week 16 follow-up
Hospitalization Events
Number of hospitalizations related to renal or cardiovascular complications.
Time frame: Baseline to Week 16
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Aug 2026, 11 months later.
Of 117 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Ace Cells Lab Limited